Vitaccess Ltd
9
2
3
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 9 trials
100.0%
+13.5% vs industry average
11%
1 trials in Phase 3/4
0%
0 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (9)
UK ENcorafenib and BInimetinib Real-world Study in Melanoma
Role: collaborator
A Study to Explore if Long-term Use of Mucinex Can Help With Symptoms in Patients With Stable Chronic Bronchitis.
Role: collaborator
Choroidal Melanoma Patient-Reported Outcome Study (CM-PRO) in a Subset of AU-011-301 (CoMpass) Subjects
Role: collaborator
Vitaccess Real MG Registry
Role: lead
Vitaccess Real CIDP Registry
Role: lead
The Impact of Charcot-Marie-Tooth Disease in the Real World
Role: lead
The Impact of Myasthenia Gravis in the Real World
Role: lead
MCT8 Deficiency Caregiver Study
Role: collaborator
The Impact of Melanoma and Drug Treatment in the Real World
Role: lead
All 9 trials loaded